Genetech Inc said it stillremains confident that it will be able to work with the U.S.Food and Drug Adminstration to obtain approval of its tissueplasminogen activator Activase for use in treating heart attackvictims.    On Friday an advisory committee of the FDA recommended thatthe blood clot dissolving drug not be approved until additionalmortality data be developed.    Genetech said it will provide the additional data andbelieves that much if not all of it is already being developed. Reuter&#3;